Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04522973 · ClinicalTrials.gov registry record · NA

The Impact of Oral Ethanol and Vaped Ethanol on the Evaluation of Impairment

A NA study of Electronic Cigarette Use, sponsored by Virginia Commonwealth University.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT04522973: Completed NA study of Electronic Cigarette Use, sponsored by Virginia Commonwealth University.

NCT04522973 is a NA study of Electronic Cigarette Use that has completed, run by Virginia Commonwealth University. The registered enrollment target is 12 participants, below the 212-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04522973, a NA study of Electronic Cigarette Use, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine if ethanol-containing e-cigarettes impact ethanol breath, blood or oral fluid tests, field sobriety tests, or other tests of sobriety. Ethanol is a common part of e-cigarette liquids.

Primary Outcome

Blood alcohol concentration (BAC) level was determined 6 times over 6 hours to assess for changes in BAC from use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol.

Conditions Studied

Interventions

  • OTHER Beverage with ethanol and E-cigarette liquid with ethanol
  • OTHER Beverage with ethanol and E-cigarette liquid without ethanol
  • OTHER Beverage without ethanol and E-cigarette liquid with ethanol
  • OTHER Beverage without ethanol and E-cigarette liquid without ethanol

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-04-21
Est. Completion 2024-07-18
Phase NA
Virginia Commonwealth University

558 total trials

What the finished NCT04522973 record still lists

NCT04522973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 212-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Electronic Cigarette Use appearing as the primary indexed condition, and to 4 interventions - of which Beverage with ethanol and E-cigarette liquid with ethanol is the first listed.

NCT04522973 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT04522973 about?

NCT04522973 is a clinical study titled "The Impact of Oral Ethanol and Vaped Ethanol on the Evaluation of Impairment". The purpose of this research study is to determine if ethanol-containing e-cigarettes impact ethanol breath, blood or oral fluid tests, field sobriety tests, or other tests of sobriety. Ethanol is a common part of e-cigarette liquids.

What is the current status of trial NCT04522973?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2023-04-21. Estimated completion is 2024-07-18.

What conditions does trial NCT04522973 study?

This clinical trial studies the following conditions: Electronic Cigarette Use.

What interventions are being tested in trial NCT04522973?

The interventions under investigation include: Beverage with ethanol and E-cigarette liquid with ethanol (OTHER), Beverage with ethanol and E-cigarette liquid without ethanol (OTHER), Beverage without ethanol and E-cigarette liquid with ethanol (OTHER), Beverage without ethanol and E-cigarette liquid without ethanol (OTHER).

Who is sponsoring clinical trial NCT04522973?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04522973 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Electronic Cigarette Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04522973's enrollment target sits among peer trials

12 16th of 15 the lowest of 15 other Electronic Cigarette Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Electronic Cigarette Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04522973, the US trial registry maintained by the National Library of Medicine. NCT04522973 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.